Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 16, 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is a transaction involving a connected person of Director Sir Andrew Witty on May 16, 2014:
- Sale: 726 Ordinary Shares sold at 1638.6078p per share.
- Repurchase: 720 Ordinary Shares repurchased at 1638.9148p per share.
- Transfer: The repurchased shares were transferred into an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the aforementioned share transactions in accordance with the Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the net change in shareholding for Sir Andrew Witty's connected person (net sale of 6 shares).
- Confirm the transaction prices (approx. 1638.6p to 1638.9p) against the market price on May 16, 2014.
- Note that this filing does not contain financial results or strategic updates for the company.